Home
Clinical Trials
Sexual Functioning Study With...

Sexual Functioning Study With Antidepressants

Last Updated: 2017-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

347 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effects of two depression medication on sexual functioning

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

NCT03420469

Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)

COMPLETED EARLY_PHASE1

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

NCT00234195

Breast Cancer Major Depressive Disorder

COMPLETED PHASE4

Wellbutrin XL for Dysthymic Disorder

NCT00225251

Dysthymic Disorder

COMPLETED PHASE4

Effects of Bupropion in Depression

NCT02104128

Depression

COMPLETED NA

To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions

NCT00861939

Depression

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/day) and Extended-release Venlafaxine (EFFEXOR XR, 75-225 mg/day) in Subjects with Major Depressive Disorder

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major Major Depressive Disorder (MDD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupropion Hydrochloride Extended-release

Intervention Type DRUG

Extended-release Venlafaxine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bupropion Hydrochloride Extended-release

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary diagnosis of Major Depressive Disorder (MDD)
* must have met DSM-IV criteria for current major depressive episode for at least 8 weeks but no long than 2 years.
* HAM-D17 total score of \>17 at screening and baseline.
* Severity of illness score of \>4 at screening and baseline.
* Willing to discuss sexual functioning with investigator or designee.
* Sexual activity that leads to orgasm at least every 2 weeks.

Exclusion Criteria

* Past or current DSM-IV diagnosis of Bipolar Disorder I or II, schizophrenia or another psychotic disorder(s).
* Primary DSM-IV diagnosis or received treatment for Panic Disorder, Obsessive Compulsive Disorder or Post Stress Disorder within previous 12 months.
* Poses a homicidal or serious suicidal risk, have made an attempt within months prior to screening or who has ever been homicidal.
* Myocardial infarction with 1 year of screening.
* Taken ibupropion hydrochloride or venlafaxine in the last 6 months.
* Positive urine test for illicit drug use or alcohol or substance abuse within the past 12 months.
* Psychotherapy within 3 months.
* Pregnant.
* Electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior of screening.
* ECG or clinical evidence of atrial or ventricular hypertrophy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers